Corbus PharmaceuticalsCRBP
CRBP
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
747% more call options, than puts
Call options by funds: $6.57M | Put options by funds: $776K
55% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 22
7% less funds holding
Funds holding: 107 [Q3] → 99 (-8) [Q4]
7.81% less ownership
Funds ownership: 97.73% [Q3] → 89.92% (-7.81%) [Q4]
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
47% less capital invested
Capital invested by funds: $243M [Q3] → $129M (-$114M) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 0 (-2) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$50
743%
upside
Avg. target
$59
901%
upside
High target
$75
1,165%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andres Maldonado 24% 1-year accuracy 12 / 50 met price target | 743%upside $50 | Buy Reiterated | 12 Mar 2025 |
Jefferies Maury Raycroft 0% 1-year accuracy 0 / 8 met price target | 794%upside $53 | Buy Maintained | 11 Mar 2025 |
HC Wainwright & Co. Andrew Fein 33% 1-year accuracy 118 / 358 met price target | 1,165%upside $75 | Buy Reiterated | 18 Feb 2025 |
Financial journalist opinion
Based on 3 articles about CRBP published over the past 30 days
Negative
Zacks Investment Research
6 days ago
After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Negative
Zacks Investment Research
1 week ago
After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals (CRBP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Positive
Zacks Investment Research
1 week ago
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
1 month ago
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025
NORWOOD, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) (“Corbus” or the “Company”), announced that data from its US and UK conducted first-in-human dose escalation clinical study (“Western study”) of CRB-701 (SYS6002) is being presented today at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
Neutral
GlobeNewsWire
1 month ago
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe (“Western study”) of CRB-701 (SYS6002) has been released. The corresponding up-to-date data will be presented as a poster during the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The data from 31 patients referred to in the abstract dates to September 2024; the upcoming poster presentation will include data on 38 patients as of December 2024. ASCO GU will be held in San Francisco, CA February 13-15, 2025.
Neutral
GlobeNewsWire
1 month ago
Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference
NORWOOD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the Guggenheim SMID Cap Biotech Conference, to be held February 5-6, 2025 in New York, NY Dr. Cohen will participate in analyst led fireside discussion and will attend one-on-one investor meetings.
Neutral
GlobeNewsWire
2 months ago
Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NORWOOD, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the 43rd Annual J.P. Morgan Healthcare Conference, to be held January 13-16, 2025 in San Francisco, CA. Dr. Cohen will be presenting and attending investor meetings.
Neutral
GlobeNewsWire
3 months ago
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment
Neutral
GlobeNewsWire
3 months ago
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
NORWOOD, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer. CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4 that contains a site-specific, cleavable linker and a precise drug antibody ratio of 2 using MMAE as the payload.
Neutral
Seeking Alpha
4 months ago
Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies
Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials and CRB-913 targeting obesity with potentially fewer CNS side effects. Despite early-stage pipeline risks, CRBP's recent sell-off offers a favorable entry point for speculative investors, upgrading my rating from "Hold" to "Speculative Buy." CRBP's valuation is compelling with $159.4 million in liquidity and no significant debt, providing a healthy cash runway.
Charts implemented using Lightweight Charts™